Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19

References

• Sahu KK, Mishra AK, Lal A. Novel coronavirus (2019-nCoV): update on 3rd coronavirus outbreak of 21st Century. QJM. 2020;113(5):384-386.
   Web of Science ®Google Scholar
• Haładyj E, Sikora M, Felis-Giemza A, et al. Antimalarials - are they effective and safe in rheumatic diseases? Reumatologia. 2018;56(3):164–173.
   PubMedGoogle Scholar
• Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608–1621.
   PubMed Web of Science ®Google Scholar
• Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30(4):297–308.
   PubMed Web of Science ®Google Scholar
• Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol. 2001;20(3):137–140.
   PubMed Web of Science ®Google Scholar
• Tsiang H, Superti F. Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells. Brief Rep Arch Virol. 1984;81(3–4):377–382.
   PubMed Web of Science ®Google Scholar
• Kronenberger P, Vrijsen R, Boeyé A. Chloroquine induces empty capsid formation during poliovirus eclipse. J Virol. 1991;65(12):7008–7011.
   PubMed Web of Science ®Google Scholar
• Mizui T, Yamashina S, Tanida I, et al. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol. 2010;45(2):195–203.
   PubMed Web of Science ®Google Scholar
• Shah PP, Wang T, Kaletsky RL, et al. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharmacol. 2010;78(2):319–324.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
   PubMed Web of Science ®Google Scholar
• Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006;49(9):2845–2849.
   PubMed Web of Science ®Google Scholar
• Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264–268.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
   PubMed Web of Science ®Google Scholar
• Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416–3421.
   PubMed Web of Science ®Google Scholar
• Niu J, Shen L, Huang B, et al. Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res. 2020;173:104646.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa237.
   Web of Science ®Google Scholar
• Simmons G, Zmora P, Gierer S, et al. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res. 2013;100(3):605–614.
   PubMed Web of Science ®Google Scholar
• Verma DK, Gupta D, Lal SK. Host lipid rafts play a major role in binding and endocytosis of influenza a virus. Viruses. 2018;10(11):650.
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem Biophys Res Commun. 2008;369(2):344–349.
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Walls AC, Lang Y, et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. 2019;26(6):481–489.
   PubMed Web of Science ®Google Scholar
• Matrosovich M, Herrler G, Klenk HD. Sialic acid receptors of viruses. Top Curr Chem. 2015;367:1–28.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Fantini J, Di Scala C, Chahinian H, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960.
   PubMed Web of Science ®Google Scholar
• Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry. 2004;43(15):4538–4547.
   PubMed Web of Science ®Google Scholar
• Varki A. Sialic acids as ligands in recognition phenomena. Faseb J. 1997;11(4):248–255.
   PubMed Web of Science ®Google Scholar
• Heald-Sargent T, Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses. 2012;4(4):557–580.
   PubMed Web of Science ®Google Scholar
• Belouzard S, Millet JK, Licitra BN, et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–1033.
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134.
   PubMed Web of Science ®Google Scholar
• Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol. 2013;87(10):5502–5511.
   PubMed Web of Science ®Google Scholar
• Kawase M, Shirato K, Matsuyama S, et al. Protease-mediated entry via the endosome of human coronavirus 229E. J Virol. 2009;83(2):712–721.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Hingley ST, Simmons G, et al. Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J Virol. 2006;80(12):5768–5776.
   PubMed Web of Science ®Google Scholar
• Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293.
   PubMedGoogle Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Narayanan K, Mizutani T, et al. Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells. J Virol. 2002;76(12):5937–5948.
   PubMed Web of Science ®Google Scholar
• Kopecky-Bromberg SA, Martinez-Sobrido L, Palese P. 7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. J Virol. 2006;80(2):785–793.
   PubMed Web of Science ®Google Scholar
• Kono M, Tatsumi K, Imai AM, et al. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 2008;77(2):150–152.
   PubMed Web of Science ®Google Scholar
• Wang LF, Lin YS, Huang NC, et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015;35(3):143–156.
   PubMed Web of Science ®Google Scholar
• Lotteau V, Teyton L, Peleraux A, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature. 1990;348(6302):600–605.
   PubMed Web of Science ®Google Scholar
• Wu SF, Chang CB, Hsu JM, et al. Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther. 2017;19(1):183.
   PubMedGoogle Scholar
• Jang CH, Choi JH, Byun MS, et al. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford). 2006;45(6):703–710.
   PubMed Web of Science ®Google Scholar
• Ewald SE, Lee BL, Lau L, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature. 2008;456(7222):658–662.
   PubMed Web of Science ®Google Scholar
• An J, Woodward JJ, Sasaki T, et al. Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol. 2015;194(9):4089–4093.
   PubMed Web of Science ®Google Scholar
• Löffler BM, Bohn E, Hesse B, et al. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim Biophys Acta. 1985;835(3):448–455.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73.
   PubMed Web of Science ®Google Scholar
• Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection a randomized clinical. JAMA Network Open. 2020;3(4):e208857.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv Preprint. 2020. DOI:10.1101/2020.03.22.20040758.
   Google Scholar
• Rathi S, Lsh P, Kalantri A, et al. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020. DOI:10.1016/S1473-3099(20)30313-3
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020. DOI:10.1016/S1473-3099(20)30296-6
   PubMed Web of Science ®Google Scholar
• Mahévas M, Tran V-T, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial. medRxiv Preprint. 2020. DOI:10.1101/2020.04.10.20060699.
   Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020. DOI:10.1056/NEJMoa2012410.
   PubMed Web of Science ®Google Scholar
• Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. China Life Sci. 2020. DOI:10.1007/s11427-020-1732-2.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. DOI:10.1016/j.ijantimicag.2020.105949.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663.
   Web of Science ®Google Scholar
• Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv Preprint. 2020. DOI:10.1101/2020.04.16.20065920.
   Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020. DOI:10.1001/jama.2020.8630.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. DOI:10.1016/S0140-6736(20)31180-6
   Web of Science ®Google Scholar
• Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93–129.
   PubMed Web of Science ®Google Scholar
• Good MI, Shader RI. Lethality and behavioral side effects of chloroquine. J Clin Psychopharmacol. 1982;2(1):40–47.
   PubMed Web of Science ®Google Scholar
• McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75(1A):11–18.
   PubMed Web of Science ®Google Scholar
• Jorge A, Ung C, Young LH, et al. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14(12):693–703.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–729.
   PubMed Web of Science ®Google Scholar
• Perinel S, Launay M, É B-N, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa394.
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. DOI:10.1001/jamacardio.2020.1834.
   PubMed Web of Science ®Google Scholar
• Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treatedwithhydroxychloroquinealone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020. DOI:10.1001/jamacardio.2020.1787.
   PubMed Web of Science ®Google Scholar
• Phru CS, Kibria MG, Thriemer K, et al. Case report: a case of primaquine-induced hemoglobinuria in glucose-6-phosphate dehydrogenase deficient malaria patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2020;102(1):156–158.
   PubMed Web of Science ®Google Scholar
• Madrid PB, Chopra S, Manger ID, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013;8(4):e60579.
   PubMed Web of Science ®Google Scholar
• Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. 2015;96(12):3484–3492.
   PubMed Web of Science ®Google Scholar
• Roques P, Thiberville SD, Dupuis-Maguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses. 2018;10(5):268.
   PubMed Web of Science ®Google Scholar